Navigating TSLA's Turns
by Mike Paulenoff
December 13, 2020 • 11:18 AM EST
Early on December 3, after Goldman Sachs upgraded TSLA to Buy from Neutral and raised its 12-month target price 780, a full 31% from its then price of 592, Mike Paulenoff wrote MPTrader members:
"I wonder whether or not its (Goldman Sachs) newfound bullishness is a contrary indication, like putting a bull on the cover of Barron's or Time magazine? As for the technical set up in TSLA, my attached chart work argues for a new all time high above 607.80 into the 630 area prior to a meaningful correction into the 500 area, and then, depending on the set-up, maybe TSLA pivots to the upside into a run towards the GS target of 780."
Mike got his expected spike, with TSLA reaching a new regular trading hours high at 654.32 on Wednesday December 9.
Plus he got his expected sell-off and upside pivot, as from there the stock peaked and then corrected to a 566.24 low on Thursday morning, prior to a vicious upside reversal that saw the stock close the week at 609.99. Has TSLA initiated its next powerful upleg that will propel the stock towards Goldman's target of 780?
Join Mike in his live MPTrader room for his forward-looking, out-of-the-box interpretation of TSLA's technical set-ups that inform members' expectations about positioning, risk management, and projected target zones for TSLA as well as for numerous other stocks, ETFs, indices, and commodities.
Mike Paulenoff is the author of MPTrader.com, a real-time diary of his technical analysis & trade alerts on
ETFs for precious metals, energy, currencies, and an array of equity indices and sectors, including international
markets, plus key ETF component stocks in sectors like technology, mining, and banking.
Sign up for a Free 7-day Trial!
More Top Calls From Mike
On March 8th, when XLI was trading at 95.88, this is what Mike Paulenoff discussed with our MPTrader Members about the S&P Industrial SPDR ETF:
"In addition to the XLB (Materials SPDR), another vehicle (arguably a better one) to ride the infrastructure spending narrative, is via the XLI Industrial ETF.
Soliton (SOLY) rallied 37% in the weeks after Mike Paulenoff highlighted it for MPTrader members on March 10. Where's it headed next?
SOLY is a medical device/biotech company developing a promising product, with a 2-year chart setup that caught Mike's attention early in the year, suggesting sooner than later that price would reflect the underlying company fundamentals.
Early on March 10, with the stock at 13.
On Monday morning March 1, Mike Paulenoff alerted MPTrader members to a potential up-move in U.S. Steel (X):
"If an infrastructure plan really is doable early in the Biden Administration, and if the 440% upmove from the March 2020 low to the Jan. 2021 high has not discounted just about every conceivable growth scenario, then X is turning up into another upleg as we speak. As long as any forthcoming weakness is contained in the 16.40 to 15.
A biotech name closely monitored in our discussion room at MPTrader and that has been on Mike's radar since the stock's explosive upmove during the height of the Covid vaccine and therapeutic drug hype last July-August is Sorrento Therapeutics (SRNE).
Mike frequently discusses the technical set up in SRNE overlaid on related company news about developmental drugs in its pipeline, and its sizable and significant short position.
Ten days ago, on February 17, Mike Paulenoff posted a detailed analysis of the bond market for MPTrader members.
In it, Mike highlighted the "increasing fear" in the bond market, with longer-term rates projected to continue to rise, and in the "Fear Index" itself, the VIX, suggesting increased risk in the equity markets.
